Home >> Research Area >>Neuroscience>>AChR>> Rivastigmine

Rivastigmine

Cholinesterase inhibitor CAS# 123441-03-2

Rivastigmine

Catalog No. BCC1900----Order now to get a substantial discount!

Product Name & Size Price Stock
Rivastigmine: 5mg $12 In Stock
Rivastigmine: 10mg Please Inquire In Stock
Rivastigmine: 20mg Please Inquire Please Inquire
Rivastigmine: 50mg Please Inquire Please Inquire
Rivastigmine: 100mg Please Inquire Please Inquire
Rivastigmine: 200mg Please Inquire Please Inquire
Rivastigmine: 500mg Please Inquire Please Inquire
Rivastigmine: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of Rivastigmine

Number of papers citing our products

Chemical structure

Rivastigmine

3D structure

Chemical Properties of Rivastigmine

Cas No. 123441-03-2 SDF Download SDF
PubChem ID 77991 Appearance Powder
Formula C14H22N2O2 M.Wt 250.34
Type of Compound N/A Storage Desiccate at -20°C
Synonyms S-Rivastigmine
Solubility DMSO : ≥ 50 mg/mL (199.73 mM)
*"≥" means soluble, but saturation unknown.
Chemical Name [3-[(1S)-1-(dimethylamino)ethyl]phenyl] N-ethyl-N-methylcarbamate
SMILES CCN(C)C(=O)OC1=CC=CC(=C1)C(C)N(C)C
Standard InChIKey XSVMFMHYUFZWBK-NSHDSACASA-N
Standard InChI InChI=1S/C14H22N2O2/c1-6-16(5)14(17)18-13-9-7-8-12(10-13)11(2)15(3)4/h7-11H,6H2,1-5H3/t11-/m0/s1
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of Rivastigmine

DescriptionRivastigmine, an cholinesterase inhibitor(IC50= 5.5 uM), inhibits both butyrylcholinesterase and acetylcholinesterase IC50 value: 5.5 uM Target: AChE Rivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease. The drug can be administered orally or via a transdermal patch; the latter form reduces the prevalence of side effects, which typically include nausea and vomiting. The drug is eliminated through the urine, and appears to have relatively few drug-drug interactions. Rivastigmine, a cholinesterase inhibitor, inhibits both butyrylcholinesterase and acetylcholinesterase. It is thought to work by inhibiting these cholinesterase enzymes, which would otherwise break down the brain chemical acetylcholine.

References:
[1]. Kurz A, Farlow M, Lefèvre G. Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer's disease: a review. Int J Clin Pract. 2009 May;63(5):799-805. [2]. Polinsky RJ. Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Clin Ther. 1998 Jul-Aug;20(4):634-47. [3]. Stryjer R, Ophir D, Bar F et al. Rivastigmine treatment for the prevention of electroconvulsive therapy-induced memory deficits in patients with schizophrenia. Clin Neuropharmacol. 2012 Jul-Aug;35(4):161-4. [4]. Han HJ, Lee JJ, Park SA et al. Efficacy and safety of switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch in patients with probable Alzheimer's disease. J Clin Neurol. 2011 Sep;7(3):137-42.

Rivastigmine Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Rivastigmine Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Rivastigmine

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 3.9946 mL 19.9728 mL 39.9457 mL 79.8913 mL 99.8642 mL
5 mM 0.7989 mL 3.9946 mL 7.9891 mL 15.9783 mL 19.9728 mL
10 mM 0.3995 mL 1.9973 mL 3.9946 mL 7.9891 mL 9.9864 mL
50 mM 0.0799 mL 0.3995 mL 0.7989 mL 1.5978 mL 1.9973 mL
100 mM 0.0399 mL 0.1997 mL 0.3995 mL 0.7989 mL 0.9986 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on Rivastigmine

Rivastigmine tartrate, an cholinesterase inhibitor(IC50= 5.5 uM), inhibits both butyrylcholinesterase and acetylcholinesterase.

Featured Products
New Products
 

References on Rivastigmine

Enhancement of oral bioavailability of rivastigmine with quercetin nanoparticles by inhibiting CYP3A4 and esterases.[Pubmed:28189992]

Pharmacol Rep. 2017 Apr;69(2):365-370.

BACKGROUND: Quercetin is a well-known flavonoid, has pharmacokinetic interaction with ester drugs due to its capability of esterase inhibition in the gut and liver. However, the interaction between quercetin nanoparticles (NQC) and Rivastigmine has not been reported. Hence, the present study was performed to evaluate the effect of quercetin alone and its nanoparticles on the pharmacokinetics of Rivastigmine in rats. METHODS: NQC prepared by antisolvent precipitation method. The influence of quercetin on the pharmacokinetics of Rivastigmine was evaluated by following methods i.e. in vitro inhibitory effect on esterase enzyme in rat liver microsomes and in vitro assessment of CYP3A activity using erythromycin-N-demethylase (EMD) assay. To confirm these findings, an in vivo pharmacokinetic study of orally administered Rivastigmine in rats with quercetin and NQC pretreatments was performed. RESULTS: The size of NQC was observed below 300nm. Quercetin significantly (p<0.05) inhibited the esterase-mediated metabolism of Rivastigmine. In in vitro assessment of CYP3A activity model the erythromycin-N-demethylation (EMD) levels in quercetin treated group were significantly reduced (p<0.05). Cmax, AUC0-t and AUC0- infinity of Rivastigmine were found to be increased in quercetin and NQC pretreated groups. Further, the CL/F and Vd/F of Rivastigmine were significantly decreased. CONCLUSIONS: The results revealed that enhanced bioavailability of Rivastigmine might be caused by the combination of their effects due to CYP3A and esterase inhibition, Therefore, concomitant administration of NQC influences the bioavailability of Rivastigmine and also has synergetic effect in the treatment of Alzheimer's disease.

Development of a Discriminative In Vitro Release Test for Rivastigmine Transdermal Patches Using Pharmacopeial Apparatuses: USP 5 and USP 6.[Pubmed:28224389]

AAPS PharmSciTech. 2017 Oct;18(7):2561-2569.

The aim of this study was to develop and validate a discriminating in vitro release test to evaluate Rivastigmine transdermal patches. The Exelon(R) Patch was chosen as a model transdermal product. The studies of in vitro release were designed to determine the impact of the official apparatus chosen (USP apparatus 5 and USP apparatus 6), the rotation speed, and the dissolution medium characteristics on the Rivastigmine release profile from transdermal patches. Patches with different drug release profiles were tested in order to evaluate the discriminating power of the in vitro release test developed and validated. Variables such as the apparatus type, the dissolution medium, and the rotation speed have a significant influence on the drug release characteristics from a transdermal patch. The in vitro release methodologies using the USP apparatus 5 at 50 rpm and USP apparatus 6 at 25 rpm using the medium phosphate-buffered saline pH 7.4 were considered discriminative and adequate to characterize the Rivastigmine (RV) release from a commercial transdermal patch, Exelon(R) Patch.

The First Use of Pralidoxime in a Child With Rivastigmine Poisoning.[Pubmed:28328690]

Pediatr Emerg Care. 2018 Oct;34(10):e184-e186.

The aim of this report is to describe the successful use of pralidoxime in a pediatric patient who accidentally ingested 12 mg of Rivastigmine and presented to the emergency department with weakness, drowsiness, hyporeactivity to environmental stimuli, and full cholinergic syndrome. CASE: The patient presented to the emergency department 2 hours after a suspected ingestion of Rivastigmine. He was sleepy but oriented and cooperative, hypotonic, and hyporeflexic and has a Glasgow Coma Scale score of 13 (E3M6V4). Laboratory tests showed a low plasma cholinesterase levels of 2141 U/L (reference range, 5300-12 900 U/L), hyperglycemia (251 mg/dL), and leukocytosis with neutrophilia (21 900/mL, 75.2% neutrophils). CONCLUSIONS: Only 2 pediatric cases of Rivastigmine poisoning have been reported in the literature, and there are no previous reports of using pralidoxime in the management of this poisoning. In the present case, intravenous pralidoxime (30 mg/kg) was administered twice at the fifth and sixth hours of ingestion for nicotinic and central effects. There is reasonable theoretical science to suggest pralidoxime in case of acetylcholinesterase inhibitor toxicity. We conclude that observed clinical improvement in weakness temporally associated with pralidoxime administration. Increased plasma cholinesterase activity after pralidoxime administration also makes it useful in this type of poisoning.

Description

Rivastigmine, an cholinesterase inhibitor(IC50= 5.5 uM), inhibits both butyrylcholinesterase and acetylcholinesterase IC50 value: 5.5 uM Target: AChE Rivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease.

Keywords:

Rivastigmine,123441-03-2,S-Rivastigmine,Natural Products,AChR, buy Rivastigmine , Rivastigmine supplier , purchase Rivastigmine , Rivastigmine cost , Rivastigmine manufacturer , order Rivastigmine , high purity Rivastigmine

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: